BioInvent International AB (publ)
BOVNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | -0.01 | 0.99 | -0.13 |
| FCF Yield | -11.43% | -11.40% | -1.78% | -7.98% |
| EV / EBITDA | -6.52 | -9.20 | -92.92 | -8.97 |
| Quality | ||||
| ROIC | -52.17% | -27.77% | -3.12% | -19.95% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.81 | 1.03 | 0.81 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -48.45% | 54.48% | 30.31% | -40.87% |
| Free Cash Flow Growth | -10.00% | -562.25% | 79.31% | -273.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.91 | 0.76 | 17.99 | 3.35 |
| Interest Coverage | -848.75 | -579.85 | -78.34 | -538.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 67.51 | 60.93 | 40.94 | 176.89 |